Form 13-F position report

KINIKSA PHARMACEUTICALS INTL

Reported by BAKER BROS ADVISORS LP

KNSA CUSIP G52694109 Manager CIK 0001263508

Reported 2,834,643 shares, unchanged from the prior quarter.

Reported value 16.7%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 1.0% This manager · Q3 2026
Shares 2,834,643 Quarter-end amount reported
Reported value $211,492,714 Fair value at quarter end
Consecutive quarters held 10 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2024-06-30 52618090
2024-09-30 70429892
2024-12-31 55746429
2025-03-31 62594954
2025-06-30 78158591
2025-09-30 109681897
2025-12-31 116582648
2026-03-31 136083745
2026-06-30 181275420
2026-09-30 211492714

Quarterly position history

How this manager's reported quarter-end position changed over time.

10 quarters
Quarterly reported position history for KINIKSA PHARMACEUTICALS INTL held by BAKER BROS ADVISORS LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Unchanged 2,834,643 0 (0.0%) 1.0% $211,492,714 2026-11-16
Q2 2026 Added 2,834,643 +8,397 (0.3%) 0.91% $181,275,420 2026-08-14
Q1 2026 Unchanged 2,826,246 0 (0.0%) 0.78% $136,083,745 2026-05-15
Q4 2025 Added 2,826,246 +1,577 (0.1%) 0.68% $116,582,648 2026-02-17
Q3 2025 Unchanged 2,824,669 0 (0.0%) 0.79% $109,681,897 2025-11-14
Q2 2025 Added 2,824,669 +6,346 (0.2%) 0.76% $78,158,591 2025-08-14
Q1 2025 Unchanged 2,818,323 0 (0.0%) 0.69% $62,594,954 2025-05-15
Q4 2024 Unchanged 2,818,323 0 (0.0%) 0.6% $55,746,429 2025-02-14
Q3 2024 Unchanged 2,818,323 0 (0.0%) 0.73% $70,429,892 2024-11-14
Q2 2024 New 2,818,323 +2,818,323 (0.0%) 0.67% $52,618,090 2024-08-14

Who else reported the position

328 managers reported KINIKSA PHARMACEUTICALS INTL for Q3 2026.

Managers reporting KINIKSA PHARMACEUTICALS INTL in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Added 7,487,391 +516,030 0.02% $558,634,260 10 qtrs
BlackRock Inc Added 2,943,674 +204,059 < 0.01% $219,627,516 9 qtrs
BAKER BROS ADVISORS LP This report Unchanged 2,834,643 0 1.0% $211,492,714 10 qtrs
Rubric Capital Management LP Reduced 2,813,469 -1,186,331 1.97% $209,912,922 10 qtrs
TANG CAPITAL MANAGEMENT LLC Unchanged 2,259,889 0 7.76% $168,610,318 10 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 2,030,666 +119,331 < 0.01% $151,507,990 3 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 1,433,679 +72,839 < 0.01% $106,966,790 3 qtrs
ARROWSTREET CAPITAL LIMITED PARTNERSHIP Added 1,093,930 +136,416 0.03% $81,618,117 10 qtrs
MORGAN STANLEY Reduced 936,373 -74,770 < 0.01% $69,862,871 10 qtrs
STATE STREET CORPORATION Added 926,267 +222,073 < 0.01% $69,108,781 10 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
ORD SHS CL A

Voting authority reported

Sole
2,834,643
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.